Gencurix Inc

229000 · KQ · Healthcare / Diagnostics & Research

1,957.00KRW+17.00 (+0.88%)

Price History

Full chart

Market Stats

Previous Close1,940.00

Open1,940.00

Day Range1,910.00 – 2,050.00

52-Week Range1,321.00 – 7,320.00

Volume0

Market Cap47.30B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta1.78

50-Day Avg1,821.58

200-Day Avg2,227.98

About

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOSung-Rai Cho
Employees0
HeadquartersHanhwa Bizmetro, Seoul, South Korea, 152-733, Korea
Websitehttps://www.gencurix.com

Leadership

Sung-Rai ChoChief Executive Officer

Financials

Income Statement

Currency: KRW	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	577.79M	585.81M	6.73M	252.32M	136.62M	1.57B	3.05B	2.56B	2.60B	5.13B	7.55B
Growth (%)	-	+1.39%	-98.85%	+3648.59%	-45.86%	+1050.64%	+93.83%	-16.00%	+1.60%	+97.43%	+47.03%
Cost of Revenue	468.32M	564.27M	0	124.67M	128.55M	2.82B	6.02B	1.40B	1.25B	1.36B	1.56B
Gross Profit	109.47M	21.54M	6.73M	127.65M	8.07M	-1.25B	-2.98B	1.16B	1.35B	3.78B	5.99B
Gross Margin	18.95%	3.68%	100.00%	50.59%	5.91%	-79.53%	-97.73%	45.23%	51.85%	73.59%	79.37%
Operating Expense	4.06B	8.18B	6.33B	5.84B	9.12B	6.83B	9.49B	15.31B	12.49B	6.48B	11.94B
Operating Income	-3.95B	-8.16B	-6.33B	-5.71B	-9.11B	-8.08B	-12.47B	-14.15B	-11.15B	-2.70B	-5.95B
Operating Margin	-684.42%	-1392.46%	-94010.08%	-2262.01%	-6670.20%	-514.05%	-409.18%	-553.01%	-428.63%	-52.57%	-78.83%
EBITDA	-	-	-	-	-	-	-	-24.06B	-18.09B	-1.89B	-5.02B
EBITDA Margin	-	-	-	-	-	-	-	-940.00%	-695.81%	-36.89%	-66.51%
Net Income	-3.98B	-9.06B	-6.82B	-5.72B	-9.16B	33.11B	-34.67B	-24.60B	-19.26B	-3.63B	-7.39B
Net Income Margin	-689.16%	-1547.25%	-101319.51%	-2268.73%	-6706.45%	2106.14%	-1137.86%	-961.01%	-740.68%	-70.63%	-97.85%
R&D	-	-	-	-	2.20B	3.15B	3.47B	4.18B	4.53B	4.22B	2.97B
R&D as % of Total Revenue	-	-	-	-	1612.57%	200.62%	114.04%	163.36%	174.16%	82.23%	39.38%
Interest Expense	0	0	0	0	76.10M	230.50M	278.21M	478.25M	810.73M	767.02M	721.63M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	55.70%	14.66%	9.13%	18.69%	31.18%	14.94%	9.56%

Balance Sheet

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	9.23B	7.36B	10.14B	2.39B	63.98B	55.29B	37.24B	33.50B	30.04B	32.11B
Total Liabilities	1.03B	955.78M	943.77M	2.23B	10.60B	24.30B	30.76B	21.50B	15.15B	15.74B
Total Equity	8.20B	6.41B	9.20B	155.18M	53.38B	30.99B	6.48B	13.78B	14.90B	16.37B
Cash	-	203.00K	352.00K	561.54M	5.63B	251.00K	643.00K	2.93B	83.00K	9.05B
Total Debt	-	-	-	859.41M	1.46B	-	-	-	-	-
Net Debt	-	-	-	-	-	-	1.99B	13.79B	9.47B	622.50M

Cash Flow

Currency: KRW	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-2.27B	-5.98B	-5.41B	-5.03B	-5.22B	-13.59B	-8.37B	-10.45B	-10.86B	-7.17B	-6.24B
Investing Cash Flow	-2.73B	-1.53B	-224.90M	-577.35M	-1.21B	-6.02B	-11.11B	-3.17B	-6.72B	5.73B	-
Financing Cash Flow	7.80B	10.00B	3.80B	8.32B	-234.08M	22.91B	25.77B	7.48B	14.65B	-732.55M	-
Capital Expenditure	1.44B	677.23M	220.10M	621.82M	814.84M	1.12B	1.08B	13.05B	2.18B	761.65M	448.71M
Free Cash Flow	-	-	-	-	-7.70B	-14.90B	-9.84B	-23.50B	-13.05B	-7.93B	-6.69B
FCF to OCF	-	-	-	-	147.54%	109.67%	117.58%	224.82%	120.19%	110.62%	107.19%

Earnings

Report Date	Jun 30, 2020	Sep 30, 2020	Mar 18, 2021	May 28, 2021	Aug 27, 2021	Nov 16, 2021	Mar 7, 2022	May 16, 2022	Aug 26, 2022	Nov 14, 2022	Mar 23, 2023	May 12, 2023	Aug 11, 2023	Nov 14, 2023	Mar 20, 2024	May 14, 2024	Aug 13, 2024	Nov 12, 2024	Mar 18, 2025	May 9, 2025	Aug 11, 2025	Nov 12, 2025	Mar 17, 2026	May 8, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-87.33	145.58	5566.48	-3676.00	1071.02	-1239.66	-1494.48	-990.21	-1515.16	-689.12	-476.36	-920.17	-505.79	-208.21	-250.23	-227.10	-280.68	-124.18	349.86	-126.46	-97.04	-126.18	-112.58	-101.19	-54.86
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	Pre-market	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-

Key Statistics & Ratios

Market Cap47.30B

Enterprise Value56.62B

Trailing P/E0.00

Forward P/E0.00

Price / Sales13.94

Price / Book3.64

Revenue (TTM)3.39B

Gross Profit (TTM)2.11B

EBITDA-9.41B

Profit Margin0.00%

Operating Margin-138.78%

Return on Equity-116.64%

Return on Assets-23.02%

Shares Outstanding24.17M

Shares Float8.38M

Beta1.78

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Mar 7, 20231651:1642